<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04479553</url>
  </required_header>
  <id_info>
    <org_study_id>QZTL-V1.0</org_study_id>
    <nct_id>NCT04479553</nct_id>
  </id_info>
  <brief_title>Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.</brief_title>
  <official_title>Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhong Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanxi Zhendong Pharmacy Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry aims to monitor the safety of Qizhi Tongluo Capsules and to identify the&#xD;
      potential risk factors for its adverse drug reactions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>The incidence of adverse drug reactions (ADR) to the Qizhi Tongluo Capsules</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse drug event (ADE) to the Qizhi Tongluo Capsules</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of new ADRs to the Qizhi Tongluo Capsules</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of serious adverse drug event (SADE) to the Qizhi Tongluo Capsules</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biological indicators of patients with serious adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Patients with serious adverse events and suspected unintended serious adverse reactions should be tested for liver function (ALT, AST, ALP, TBIL, DBIL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biological indicators of patients with serious adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Patients with serious adverse events and suspected unintended serious adverse reactions should be tested for renal function (BUN, SCr, UA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biological indicators of patients with serious adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Patients with serious adverse events and suspected unintended serious adverse reactions should be tested for immune indicators (IgA, IgE, T-lymphocyte, B lymphocyte, cell surface antigen, serum histamine concentration and complement).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>Safety Surveillance</condition>
  <condition>Adverse Drug Events</condition>
  <condition>Adverse Drug Reactions</condition>
  <condition>Severe Adverse Events</condition>
  <condition>Severe Adverse Reactions</condition>
  <arm_group>
    <arm_group_label>Qizhi Tongluo Capsules</arm_group_label>
    <description>Qizhi Tongluo Capsules will be given to the patients, and the investigators will record all the information including ADR, application of Qizhi Tongluo Capsules and the combined medications, etc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qizhi Tongluo Capsules</intervention_name>
    <description>Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).</description>
    <arm_group_label>Qizhi Tongluo Capsules</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. The blood routine, urine routine, and stool routine before and after medication need to&#xD;
           be obtained in the patients with adverse events&#xD;
&#xD;
        2. The level of the liver functional indicators (including ALT,AST,ALP,TBIL,DBIL) the renal&#xD;
           functional indicators (including BUN,SCr,UA) and the immune indicators (including&#xD;
           IgA，IgE,the counts of T lymphocyte and B lymphocyte,CD3，CD4，CD8，CD20,serum histamine&#xD;
           concentration,C3,C4) should be obtained in patients with serious adverse events and&#xD;
           suspicious unexpected serious adverse reactions.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who use Qizhi Tongluo Capsules in the monitoring hospitals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who use Qizhi Tongluo Capsules in the monitoring hospitals.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhong Wang</last_name>
    <phone>86-10-64093207</phone>
    <email>zhonw@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ningming County Hospital of Chinese Medicine</name>
      <address>
        <city>Changzuo</city>
        <state>Guangxi</state>
        <zip>532500</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fangchenggang City Hospital of Chinese Medicine</name>
      <address>
        <city>Fangchenggang</city>
        <state>Guangxi</state>
        <zip>538021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haizhen Pan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi University of Chinese Medicine</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanglin County Hospital of Chinese Medicine</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530500</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guige Tan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Long'an County Hospital of Chinese Medicine</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>532799</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenming Lu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luohe Hospital of traditional Chinese Medicine</name>
      <address>
        <city>Luohe</city>
        <state>Henan</state>
        <zip>462000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingmin Song</last_name>
      <phone>13623957063</phone>
      <email>sym26567@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanyang Medical College</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <zip>473000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanyang Medical College</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <zip>473000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanqun Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinxiang Medical University</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <zip>453199</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ping Zhang</last_name>
      <email>zhangpingsjnk@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of traditional Chinese Medicine</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinzhi Wang</last_name>
      <phone>18638189355</phone>
      <email>znqznq@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Henan University of traditional Chinese Medicine</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Yanbian University</name>
      <address>
        <city>Yanbian</city>
        <state>Jilin</state>
        <zip>133000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Shandong University of Chinese Medicine</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingchen Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Changzhi Institute of traditional Chinese Medicine</name>
      <address>
        <city>Changzhi</city>
        <state>Shanxi</state>
        <zip>046000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinbin Guo</last_name>
      <phone>13111251707</phone>
      <email>changzhizynb@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zhong Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

